Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Survival Curves01:18

Survival Curves

Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

European urology oncology·2026
Same author

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

The Lancet. Oncology·2025
Same author

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

European psychiatry : the journal of the Association of European Psychiatrists·2025
Same author

A plain language summary of LocoMMotion - an observational study of treatments used for pretreated multiple myeloma.

Future oncology (London, England)·2025
Same author

Incidence and determinants of graft failure and death with functioning graft after re-transplantation.

Pediatric nephrology (Berlin, Germany)·2025
Same journal

Modeling treatment effects on absorbing outcomes in clinical trials: Leveraging longitudinal and ordinal data for efficiency gains.

Statistical methods in medical research·2026
Same journal

A joint model for a longitudinal outcome and a progressive multistate model under a mixed observation scheme.

Statistical methods in medical research·2026
Same journal

Efficient semi-supervised estimation of optimal individualized treatment regimes with survival outcome.

Statistical methods in medical research·2026
Same journal

Asymptotic online FWER control for dependent test statistics.

Statistical methods in medical research·2026
Same journal

Regression analysis of misclassified current status data with potentially unknown test accuracy.

Statistical methods in medical research·2026
Same journal

Bayesian multivariate linear mixed-effects models with varied association structures.

Statistical methods in medical research·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Crossover studies with survival outcomes.

Jozefien Buyze1, Els Goetghebeur

  • 1Ghent University, Department of Applied Mathematics & Computer Science, Krijgslaan Gent, Belgium.

Statistical Methods in Medical Research
|July 1, 2011
PubMed
Summary
This summary is machine-generated.

Crossover designs offer significant power gains for survival data in human immunodeficiency virus (HIV) prevention studies. This design is more efficient than parallel designs, especially in heterogeneous populations.

Keywords:
HIV preventioncrossover designfrailty modelsmicrobicidessurvival analysis

Related Experiment Videos

Last Updated: May 31, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Epidemiology

Background:

  • Crossover designs are efficient for non-interacting treatments but often abandoned for survival endpoints.
  • Parallel designs are commonly used for survival data despite higher costs.
  • Human immunodeficiency virus (HIV) prevention studies have historically lacked statistical power.

Purpose of the Study:

  • To evaluate the potential gains in statistical power and efficiency of crossover designs compared to parallel designs for survival endpoints.
  • To investigate the impact of population heterogeneity and frailties on the performance of crossover designs.
  • To determine the optimal crossover time point for maximizing efficiency in survival studies.

Main Methods:

  • Comparison of parallel and crossover designs using a non-parametric logrank test for survival data.
  • Analysis using a proportional hazards model with frailties to assess subject-specific and population-averaged hazard ratios.
  • Derivation of the optimal time point for treatment crossover to enhance study efficiency.
  • Application of the methods to data from two human immunodeficiency virus (HIV) prevention trials (Cellulose sulphate and Nonoxynol-9).

Main Results:

  • Crossover designs demonstrate a substantial increase in power for survival endpoints in heterogeneous populations.
  • Subject-specific hazard ratios show significantly smaller variance in crossover designs.
  • Population-averaged hazard ratios show negligible gain initially, but efficiency is recovered through reconstruction.
  • The Cellulose sulphate trial showed minimal efficiency gain, while the Nonoxynol-9 trial exhibited substantial power improvement with a crossover design.

Conclusions:

  • Crossover designs can be highly effective and efficient for specific survival analysis problems, particularly in HIV prevention research.
  • The choice between parallel and crossover designs depends on the specific trial characteristics, including population heterogeneity and treatment effect.
  • There is a valuable role for well-designed crossover trials in addressing critical survival endpoints in various medical research areas.